Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.00% | ||
| 1 Month | -8.56% | ||
| 3 Months | -10.10% | ||
| 6 Months | -51.19% | ||
| 1 Year | - | ||
| 3 Years | -79.40% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -43.89 | |||
ROE last 12 Months | -196.77 | |||
ROA (5Y Avg) | -6.58 | |||
ROA last 12 Months | -23.34 | |||
ROC (5Y Avg) | -40.85 | |||
ROC last 12 Months | -31.14 | |||
Return on invested Capital Q | -11.58 | |||
Return on invested Capital Y | -34.57 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -4.60 | ||||
| 4.62 | ||||
| 3.75 | ||||
| - | ||||
| -11.30 | ||||
| -0.28 | ||||
| 4.52 | ||||
| 0.63 | ||||
| 75.47M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.10 | ||||
| 1.30 | ||||
| 0.11 | ||||
| 1.55 | ||||
| -3.50 | ||||
| Leverage Ratio | 3.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 86.90 | ||||
| -43.60 | ||||
| -43.60 | ||||
| -64.80 | ||||
| -79.42 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 21.38M | ||||
| 0.75 | ||||
| -0.02 | ||||
| 31.81 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2021 | - | -0.24 | - |
| Q02 2021 | - | -0.17 | - |
| Q01 2021 | - | -0.22 | - |
| Q03 2020 | - | -0.28 | - |
| Q02 2020 | - | 0.04 | - |
| Q01 2020 | - | -0.31 | - |
| Q04 2019 | - | -0.22 | - |
| Q03 2019 | - | -0.59 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 0 |
| Shares Outstanding | 0 |
| Shares Float | 0 |
| Trades Count | 0 |
| Dollar Volume | 0 |
| Avg. Volume | 0 |
| Avg. Weekly Volume | 0 |
| Avg. Monthly Volume | 0 |
| Avg. Quarterly Volume | 0 |
Biofrontera AG (NASDAQ: BFRA) stock closed at 2.67 per share at the end of the most recent trading day (a -9.49% change compared to the prior day closing price) with a volume of 4.90K shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 155 people. Biofrontera AG CEO is Hermann Lubbert.
The one-year performance of Biofrontera AG stock is %, while year-to-date (YTD) performance is -10.1%. BFRA stock has a five-year performance of %. Its 52-week range is between and , which gives BFRA stock a 52-week price range ratio of %
Biofrontera AG currently has a PE ratio of -4.60, a price-to-book (PB) ratio of 4.62, a price-to-sale (PS) ratio of 3.75, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -23.34%, a ROC of -31.14% and a ROE of -196.77%. The company’s profit margin is -79.42%, its EBITDA margin is -43.60%, and its revenue ttm is $21.38 Million , which makes it $0.75 revenue per share.
Of the last four earnings reports from Biofrontera AG, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biofrontera AG’s next earnings report date is -.
The consensus rating of Wall Street analysts for Biofrontera AG is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Biofrontera AG stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biofrontera AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biofrontera AG has a Sell technical analysis rating based on Technical Indicators (ADX : 22.88, ATR14 : 0.47, CCI20 : -35.09, Chaikin Money Flow : -0.69, MACD : -0.06, Money Flow Index : 0.00, ROC : 0.00, RSI : 42.74, STOCH (14,3) : 14.00, STOCH RSI : 0.00, UO : 15.43, Williams %R : -86.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biofrontera AG in the last 12-months were:
Biofrontera AG
Biofrontera AG is active in the field of healthcare in the United Kingdom. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.
CEO: Hermann Lubbert
Telephone: +49 2148733200
Address: Hemmelrather Weg 201, Leverkusen D-51377, , DE
Number of employees: 155
